Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network

被引:3
|
作者
Lane, Karen [1 ]
Palm, Marisha E. E. [2 ,3 ]
Marion, Eve [4 ]
Kay, Marie T. T. [5 ]
Thompson, Dixie [5 ]
Stroud, Mary [6 ]
Boyle, Helen [4 ]
Hillery, Shannon [7 ]
Nanni, Angeline [7 ]
Hildreth, Meghan [1 ]
Nelson, Sarah [8 ]
Burr, Jeri S. S. [5 ]
Edwards, Terri [6 ]
Poole, Lori [4 ]
Waddy, Salina P. P. [9 ]
Dunsmore, Sarah E. E. [9 ]
Harris, Paul [10 ]
Wilkins, Consuelo [11 ]
Bernard, Gordon R. R. [6 ]
Dean, J. Michael [5 ]
Dwyer, Jamie [5 ]
Benjamin, Daniel K. K. [4 ]
Selker, Harry P. P. [3 ,12 ,13 ]
Hanley, Daniel F. F. [14 ]
Ford, Daniel E. E. [15 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA
[2] Tufts Med Ctr, Boston, MA USA
[3] Tufts Med Ctr, Inst Clin Res, Hlth Policy Studies, Boston, MA USA
[4] Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA
[5] Univ Utah, Sch Med, Salt Lake City, UT USA
[6] Vanderbilt Univ, Vanderbilt Inst Clin & Translat Res, Med Ctr, Nashville, TN USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[9] Natl Ctr Adv Translat Sci, Div Clin Innovat, Bethesda, MD USA
[10] Vanderbilt Univ Sch Med, Nashville, TN USA
[11] Vanderbilt Univ, Dept Med, Med Ctr, Nashville, TN USA
[12] Tufts Univ, Tufts Clin & Translat Sci Inst, Boston, MA USA
[13] Tufts Med Ctr, Hlth Policy Studies, Boston, MA USA
[14] Johns Hopkins Univ, Sch Med, Acute Care Neurol, Baltimore, MD USA
[15] Johns Hopkins Univ, Inst Clin & Translat Res, Sch Med, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
Multicenter trials; informative trials; Trial Innovation Network; study planning; clinical trial budgets; clinical trial resources;
D O I
10.1017/cts.2023.560
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
One challenge for multisite clinical trials is ensuring that the conditions of an informative trial are incorporated into all aspects of trial planning and execution. The multicenter model can provide the potential for a more informative environment, but it can also place a trial at risk of becoming uninformative due to lack of rigor, quality control, or effective recruitment, resulting in premature discontinuation and/or non-publication. Key factors that support informativeness are having the right team and resources during study planning and implementation and adequate funding to support performance activities. This communication draws on the experience of the National Center for Advancing Translational Science (NCATS) Trial Innovation Network (TIN) to develop approaches for enhancing the informativeness of clinical trials. We distilled this information into three principles: (1) assemble a diverse team, (2) leverage existing processes and systems, and (3) carefully consider budgets and contracts. The TIN, comprised of NCATS, three Trial Innovation Centers, a Recruitment Innovation Center, and 60+ CTSA Program hubs, provides resources to investigators who are proposing multicenter collaborations. In addition to sharing principles that support the informativeness of clinical trials, we highlight TIN-developed resources relevant for multicenter trial initiation and conduct.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Why results from Bayesian statistical analyses of clinical trials with a strong prior and small sample sizes may be misleading The case of the NICHD Neonatal Research Network Late Hypothermia Trial
    Walloe, Lars
    Hjort, Nils Lid
    Thoresen, Marianne
    ACTA PAEDIATRICA, 2019, 108 (07) : 1190 - 1191
  • [42] Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303
    Keever-Taylor, Carolyn A.
    Devine, Steven M.
    Soiffer, Robert J.
    Mendizabal, Adam
    Carter, Shelly
    Pasquini, Marcelo C.
    Hari, Parameswaran N.
    Stein, Anthony
    Lazarus, Hillard M.
    Linker, Charles
    Goldstein, Steven C.
    Stadtmauer, Edward A.
    O'Reilly, Richard J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (05) : 690 - 697
  • [43] A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study
    Shenoy, Shalini
    Eapen, Mary
    Wu, Juan
    Walters, Mark C.
    Levine, John E.
    Logan, Brent
    Gersten, Iris D.
    Kamani, Naynesh R.
    BLOOD, 2015, 126 (23)
  • [44] Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network
    Wu, Li-Tzy
    Ling, Walter
    Burchett, Bruce
    Blazer, Dan G.
    Shostak, Jack
    Woody, George E.
    SUBSTANCE ABUSE AND REHABILITATION, 2010, 1 : 13 - 22
  • [45] Results of the Blood and Marrow Transplant Clinical Trials Network Study BMT CTN 0601: Scurt - a Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation (BMT) for Children with Severe Sickle Cell Disease
    Shenoy, Shalini
    Eapen, Mary
    Wu, Juan
    Walters, Mark C.
    Levine, John E.
    Logan, Brent R.
    Gersten, Iris D.
    Kamani, Naynesh R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S104 - S104
  • [46] Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation
    Switzer, Galen E.
    Harrington, Donna
    Haagenson, Michael D.
    Drexler, Rebecca
    Foley, Amy
    Confer, Dennis L.
    Bishop, Michelle
    Anderlini, Paolo
    Rowley, Scott D.
    Leitman, Susan
    Anasetti, Claudio
    Wingard, John R.
    BLOOD, 2010, 116 (21) : 165 - 166
  • [47] Characteristics of Primary Care Patients With Risky Opioid Use: Baseline Data From the "Subthreshold Opioid Use Disorder Prevention" (STOP) Trial of a Collaborative Care Intervention, Conducted in the NIDA Clinical Trials Network
    Abadi, Yasna Rostam
    McNeely, Jennifer
    Subramaniam, Geetha
    Stone, Rebecca
    Appleton, Noa
    Lovejoy, Travis
    Gelberg, Lillian
    Beers, Donna
    Abrams, Catherine
    Revoredo, Leslie
    McCormack, Jennifer
    Kline, Margaret
    Zhang, Song
    Kim, Tobie
    Case, Ashley
    Liebschutz, Jane
    McNeely, Jennifer
    DRUG AND ALCOHOL DEPENDENCE, 2025, 267 : 193 - 193
  • [48] The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).
    Nishihori, Taiga
    Bashir, Qaiser
    Pasquini, Marcelo C.
    Martens, Michael
    Wu, Juan
    Alsina, Melissa
    Efebera, Yvonne Adeduni
    Gasparetto, Cristina
    Geller, Nancy
    Giralt, Sergio
    Koreth, John
    McCarthy, Philip L.
    Scott, Emma Catherine
    Stadtmauer, Edward Allen
    Vesole, David H.
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.(vol 100, pg 1090, 2005)
    Ling, W.
    Amass, L.
    Shoptaw, S.
    Annon, J. J.
    Hillhouse, M.
    Babcock, D.
    Brigham, G.
    Harrer, J.
    Reid, M.
    Muir, J.
    Buchan, B.
    Orr, D.
    Woody, G.
    Krejci, J.
    Ziedonis, D.
    ADDICTION, 2006, 101 (09) : 1374 - 1374
  • [50] Impact of Short-Course Preoperative Radiotherapy for Rectal Cancer on Patients' Quality of Life: Data From the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 Randomized Clinical Trial
    Stephens, Richard J.
    Thompson, Lindsay C.
    Quirke, Phil
    Steele, Robert
    Grieve, Robert
    Couture, Jean
    Griffiths, Gareth O.
    Sebag-Montefiore, David
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4233 - 4239